Haleon plc

Haleon is a British multinational consumer healthcare company with its global headquarters in London, United Kingdom, and a registered office in Weybridge, England. The company's core business is dedicated to everyday, non-prescription health products, driven by its purpose "to deliver better everyday health with humanity." Haleon also established a new U.S. headquarters in Berkeley Heights, New Jersey, with relocation expected by late 2026.

Haleon operates across six primary categories: Oral Health, Vitamins, Minerals & Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its extensive portfolio features globally recognized brands such as Sensodyne, Advil, Centrum, Panadol, Voltaren, and Theraflu. The company distributes its products in approximately 170 markets worldwide through pharmacies, mass-market retailers, and e-commerce platforms.

Formed as an independent public company in July 2022 following its spin-off from GSK, Haleon is led by Chief Executive Officer Brian McNamara. The company's "Win as One" strategy aims to reach one billion more consumers by 2030, focusing on health inclusivity, superior brands, and digital transformation. In a notable development in July 2026, Haleon announced a five-year collaboration with Microsoft to enhance its digital, data, and AI capabilities across its global operations.